SI markers and pro-inflammatory cytokine (IL-17F and IFNα2) tend to be higher in NSCLC patients and the anti-inflammatory cytokine IL-1RA tends to be high in SCLC, which taken together suggests that NSCLC patients tend to have elevated levels of inflammation relative to those diagnosed with SCLC. This evidence concerns the gene IL17F and non-small cell lung carcinoma.